MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: Evidence from 21 case-control studies

Cancer Epidemiology Biomarkers and Prevention

Volumn 16, Issue 12, 2007, Pages 2717-2723

  Hu, Zhibin ^a   Jin, Guangfu ^a   Wang, Lu ^a   Chen, Feng ^a   Wang, Xinru ^a   Shen, Hongbing ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MDM2; PROTEIN P53; TUMOR MARKER;

ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CLINICAL TRIAL; CONFIDENCE INTERVAL; ENVIRONMENTAL STRESS; ETHNICITY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HOMOZYGOSITY; HUMAN; META ANALYSIS; PRIORITY JOURNAL; PUBLICATION; QUANTITATIVE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW;

CASE-CONTROL STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASMS; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS C-MDM2; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 38849111754     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-0634     Document Type: Article

References (53)

1. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-31.
2. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-10.
3. Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene 2005;24:2899-908.
4. Freedman DA, Levine AJ. Regulation of the p53 protein by the MDM2 oncoprotein - 38th G.H.A. Clowes Memorial Award Lecture. Cancer Res 1999;59:1-7.
5. Poyurovsky MV, Prives C. Unleashing the power of p53: lessons from mice and men. Genes Dev 2006;20:125-31.
6. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992;358:80-3.
7. Leach FS, Tokino T, Meltzer P, et al. p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 1993;53:2231-4.
8. Gudas JM, Nguyen H, Klein RC, Katayose D, Seth P, Cowan KH. Differential expression of multiple MDM2 messenger RNAs and proteins in normal and tumorigenic breast epithelial cells. Clin Cancer Res 1995;1:71-80.
9. Zhang Z, Zhang R. p53-independent activities of MDM2 and their relevance to cancer therapy. Curr Cancer Drug Targets 2005;5:9-20.
10. Barak Y, Gottlieb E, Juven-Gershon T, Oren M. Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. Genes Dev 1994;8:1739-49.
11. Zauberman A, Flusberg D, Haupt Y, Barak Y, Oren M. A functional p53-responsive intronic promoter is contained within the human mdm2 gene. Nucleic Acids Res 1995;23:2584-92.
12. Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004;119:591-602.
13. Alhopuro P, Ylisaukko-Oja SK, Koskinen WJ, et al. The MDM2 promoter polymorphism SNP309T → G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck. J Med Genet 2005;42:694-8.
14. Alazzouzi H, Suriano G, Guerra A, et al. Tumour selection advantage of non-dominant negative P53 mutations in homozygotic MDM2-309 colorectal cancer cells. J Med Genet 2007;44:75-80.
15. Boersma BJ, Howe TM, Goodman JE, et al. Association of breast cancer outcome with status of p53 and MDM2 SNP309. J Natl Cancer Inst 2006;98:911-9.
16. Campbell IG, Eccles DM, Choong DY. No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer. Cancer Lett 2006;240:195-7.
17. Li G, Zhai X, Zhang Z, Chamberlain RM, Spitz MR, Wei Q. MDM2 gene promoter polymorphisms and risk of lung cancer: a case-control analysis. Carcinogenesis 2006;27:2028-33.
18. Lind H, Zienolddiny S, Ekstrom PO, Skaug V, Haugen A. Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer. Int J Cancer 2006;119:718-21.
19. Menin C, Scaini MC, De Salvo GL, et al. Association between MDM2-309 and age at colorectal cancer diagnosis according to p53 mutation status. J Natl Cancer Inst 2006;98:285-8.
20. Millikan RC, Heard K, Winkel S, et al. No association between the MDM2-309 T/G promoter polymorphism and breast cancer in African-Americans or Whites. Cancer Epidemiol Biomarkers Prev 2006;15:175-7.
21. Onat OE, Tez M, Ozcelik T, Toruner GA. MDM2T309G polymorphism is associated with bladder cancer. Anticancer Res 2006;26:3473-5.
22. Petenkaya A, Bozkurt B, Akilli-Ozturk O, Kaya HS, Gur-Dedeoglu B, Yulug IG. Lack of association between the MDM2- 309 polymorphism and breast cancer risk. Anticancer Res 2006;26:4975-7.
23. Pine SR, Mechanic LE, Bowman ED, et al. MDM2 SNP309 and SNP354 are not associated with lung cancer risk. Cancer Epidemiol Biomarkers Prev 2006;15:1559-61.
24. Wasielewski M, Nagel JH, Brekelmans C, et al. MDM2 SNP309 accelerates familial breast carcinogenesis independently of estrogen signaling. Breast Cancer Res Treat 2007;104:153-7.
25. Wilkening S, Bermejo JL, Burwinkel B, et al. The single nucleotide polymorphism IVS1 + 309 in mouse double minute 2 does not affect risk of familial breast cancer. Cancer Res 2006;66:646-8.
26. Wilkening S, Hemminki K, Rudnai P, et al. No association between MDM2 SNP309 promoter polymorphism and basal cell carcinoma of the skin. Br J Dermatol 2007;157:375-7.
27. Dharel N, Kato N, Muroyama R, et al. MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C. Clin Cancer Res 2006;12:4867-71.
28. Hong Y, Miao X, Zhang X, et al. The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res 2005;65:9582-7.
29. Hu Z, Ma H, Lu D, et al. Genetic variants in the MDM2 promoter and lung cancer risk in a Chinese population. Int J Cancer 2006;118:1275-8.
30. Ma H, Hu Z, Zhai X, et al. Polymorphisms in the MDM2 promoter and risk of breast cancer: a case-control analysis in a Chinese population. Cancer Lett 2006;240:261-7.
31. Ohmiya N, Taguchi A, Mabuchi N, et al. MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J Clin Oncol 2006;24:4434-40.
32. Park SH, Choi JE, Kim EJ, et al. MDM2 309T>G polymorphism and risk of lung cancer in a Korean population. Lung Cancer 2006;54:19-24.
33. Zhang X, Miao X, Guo Y, et al. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum Mutat 2006;27:110-7.
34. Hirata H, Hinoda Y, Kikuno N, et al. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma. Clin Cancer Res 2007;13:4123-9.
35. Zhou G, Zhai Y, Cui Y, et al. MDM2 promoter SNP309 is associated with risk of occurrence and advanced lymph node metastasis of nasopharyngeal carcinoma in Chinese population. Clin Cancer Res 2007;13:2627-33.
36. Walsh CS, Miller CW, Karlan BY, Koeffler HP. Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk. Gynecol Oncol 2007;104:660-4.
37. 72Pro and MDM2-309 polymorphisms and risk of breast cancer in the nurses' health studies. Cancer Causes Control 2007;18:621-5.
38. Copson ER, White HE, Blaydes JP, Robinson DO, Johnson PW, Eccles DM. Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers. BMC Cancer 2006;6:80.
39. Petitti D. Meta-analysis, decision analysis, and cost-effectiveness analysis. New York, Oxford University Press; 1994.
40. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med 1997;127:820-6.
41. Whitehead A, Whitehead J. A general parametric approach to the meta-analysis of randomized clinical trials. Stat Med 1991;10:1665-77.
42. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
43. Bond GL, Hu W, Levine A. A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res 2005;65:5481-4.
44. Marchetti A, Buttitta F, Girlando S, et al. mdm2 gene alterations and mdm2 protein expression in breast carcinomas. J Pathol 1995;175:31-8.
45. Bueso-Ramos CE, Manshouri T, Haidar MA, et al. Abnormal expression of MDM-2 in breast carcinomas. Breast Cancer Res Treat 1996;37:179-88.
46. Okumura N, Saji S, Eguchi H, Nakashima S, Saji S, Hayashi S. Distinct promoter usage of mdm2 gene in human breast cancer. Oncol Rep 2002;9:557-63.
47. Phelps M, Darley M, Primrose JN, Blaydes JP. p53-independent activation of the hdm2-2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor a- positive breast cancer cells. Cancer Res 2003;63:2616-23.
48. Hu W, Feng Z, Ma L, et al. A single nucleotide polymorphism in the MDM2 gene disrupts the oscillation of p53 and MDM2 levels in cells. Cancer Res 2007;67:2757-65.
49. Bond GL, Hirshfield KM, Kirchhoff T, et al. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res 2006;66:5104-10.
50. Olivier M, Hussain SP, Caron de Fromentel C, Hainaut P, Harris CC. Tp53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. IARC Sci Publ 2004;157:247-70.
51. 72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet 2006;43:531-3.
52. Ruijs MW, Schmidt MK, Nevanlinna H, et al. The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes. Eur J Hum Genet 2007;15:110-4.
53. Tabori U, Nanda S, Druker H, Lees J, Malkin D. Younger age of cancer initiation is associated with shorter telomere length in Li-Fraumeni syndrome. Cancer Res 2007;67:1415-8.